Skip to content

Study on the changes of ocular biometrics during pharmacologic effect on accommodation states in primary angle closure disease and its clinical significance

Study on the changes of ocular biometrics during pharmacologic effect on accommodation states in primary angle closure disease and its clinical significance

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056748
Enrollment
Unknown
Registered
2022-02-13
Start date
2022-02-01
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prima angle closure disease

Interventions

PACS:Miosis
PACS:Mydriasis
PAC:Miosis
PAC:Mydriasis
PACG:Miosis
PACG:Mydriasis
Normal:Miosis
Normal:Mydriasis

Sponsors

Beijing Tongren Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily sign the informed consent of this study 2. Chinese male or female patients aged 18-80 years, including 18 and 80 years. Primary Angle-closure Glaucoma suspect (PACS) and primary Angle-closure glaucoma suspect (PACS). Clinical diagnosis of primary Angle-closure glaucoma (PACG): (1) Primary angle closure suspect: difficult to see pigment trabecular meshwork (i.e. contact of iris trabecular meshwork) by anterior chamber angle, and the IOP was 180, (or) there was adhesion of peripheral anterior chamber Angle, no glaucoma optic nerve injury, accompanied by intraocular pressure >=22mmHg; (3) PACG: meet the diagnostic conditions of PAC and have glaucomatous optic neuropathy or glaucomatous visual field defect; 4. With or without cataracts.

Exclusion criteria

Exclusion criteria: 1. Acute primary angle-closure (APAC) or ACUTE onset of PACG; 2. Unable or unwilling to sign a consent form, unable to follow study procedures, and unable to cooperate with eye examinations; 3. Secondary angle-closure glaucoma: lens dislocation, uveitis, trauma, and neovascular glaucoma; 4. Those who have had previous surgery or are expected to have other surgery: had previously undergone damaging ciliary body surgery, cataract surgery with or without IOL implantation; No lens eye; Additional eye surgery or other eye operations are expected; 5. Associated with other diseases or abnormalities of the eye, including corneal abnormalities or corneal infection; iridocorneal endothelial syndrome, anterior segment hypoplasia, nanophthalmos, high myopia (>6.0D), uveitis, ocular tumor, ocular trauma, fundus lesions such as central retinal vein obstruction, central retinal artery obstruction, retinal detachment, etc.; 6. Pregnant or Breast Feeding women or whom with a history of serious systemic diseases: diabetes, hypertension (systolic blood pressure >=180mmHg or diastolic blood pressure >=100mmHg), advanced heart disease, kidney disease, respiratory disease or tumor, etc.; 7. Patients with autoimmune diseases require long-term use of local and systemic hormones or the presence of hormone therapy.

Design outcomes

Primary

MeasureTime frame
Ultrasound biomicroscopy;Anterior segment optical coherence tomography;Swept source optical coherence tomography;AB-mode diagnostic ultrasonic apparatus;

Countries

China

Contacts

Public ContactNingli Wang

Beijing Tongren Hospital, Capital Medical University

wningli@vip.163.com+86 13511026669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026